диссертации / 10
.pdf141
105.Bhatia, M. Novel therapeutic targets for acutepancreatitis and associated multiple organ dysfunction syndrome/ M. Bhatia // Curr. Drug. Targets Inflamm Allergy.- 2002.-V.1. –P. 343–351.
106.Bonecchi, R. Upregulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN gamma in human neutrophils / R. Bonecchi, N. Polentarutti, W. Luini // J. Immunol.- 1999.-V. 162.-P. 474–479.
107.Boyum, A. Separation of leukocytes from blood and bone marrow / A. Boyum //Scand.J.Clin.Lab.Investig.-1968.-V.21-№.97.-P.1-9.
108.Carlos, T.M. Leukocyte-endothelial adhesion molecules/ T.M. Carlos, J.M. Har- lan //Blood.-1994.-V.84.- P.2068-2101.
109.Cerulein upregulates ICAM-1 in pancreatic acinar cells, which mediates neutrophil adhesion to these cells / V. Zaninovic, A.S Gukovskaya., I. Gukovsky, et al. //Am. J. Physiol. Gastrointest. Liver Physiol. - 2000.-V.279.-P.G666–G676.
110.Chemiluminescence detection of H2O2 produced by human neutrophils during the respiratory burst / M.P. Wymann, V. Tscharner, Deranleau, M. Baggilioni //Anal.Biochem.-1987.-V.165.-№2.-P.371-378.
111.Chronic alcohol consumption is a major risk factor for pancreatic necrosis in acute pancreatitis/ G.I. Papachristou, D.J. Papachristou, V.D. Morinville, et al. // Am J Gastroenterol.-2006.-V.101.-P.2605-2610.
112.Croton, R.S. Ionized calcium in acute pancreatitis and its relationship with total calcium and serum lipase/ R.S. Croton, R.A. Watter, N.B. Roberts //Brit.J.Surg.- 1981.-V.68.-№2.-P.241-244.
113.Dahlgren, C. Respiratory burst in human neutrophils / C. Dahlgren, A. Karlsson //J.Immunol.met. -1999.-V.232.-P.3-14.
114.Dambrauskas, Z. Predicting development of infected necrosis in acute necrotizing pancreatitis / Z. Dambrauskas, J. Pundzius, G. Barauskas //Medicina (Kau- nas).-2006.-Vol.42.-№6.- P.441-449.
142
115.Diagnostic relevance of procalcitonin, IL-6, and sICAM-1 in the prediction of infected necrosis in acute pancreatitis/ Y. Mandi, G. Farcas, T. Takacs, et al. //Int J Pancreatology .-2000.-V.28.-№1.-P.41-49.
116.Differential effects of bacterial lipopolysaccharides upon neutrophil function / M.-H.Ruchaud-Sparagano, C.A. Ruivenkamp et al.// FEBS Lett.- 1998.-V.430.-
№3.- P.363–369.
117.Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT) / B.M. Rau, E.A. Kemppainen, A.A. Gumbs, et al. // Annals of Surgery.-2007.-V.245.- №5.-P.745-754.
118.Frequency and time course of pancreatic and extrapancreatic bacterial infection in experimental acute pancreatitis in rats/ M. Schwarz, J. Thomsen, H. Meyer, et al. //Surgery. - 2000. - V.127. - №4. – P.427-432.
119.Frossard, J-L. New serum markers for the detection of severe acute pancreatitis in humans/ J-L. Frossard, A. Hadengue, C.M. Pastor // Amer. J. Respir. Crit. Care Med.- 2001.-V.164.-P.162-170.
120.Gastric colonization, intestinal permeability and septic morbility in acute pancreatitis/ C.E. McNaught, N.P. Woodcock, C.J. Mitchell, et al. //Pancreatology.- 2002.- №2. – P.463-468.
121.Granulocyte elastase in assessment of severity of acute pancreatitis/ Dr.V.Gross, J. Schölmerich, H-G. Leser, et al. //Digestive diseases and sciences.- 1990.-V35.-
№1.-P.99-105.
122.Granulocyte-colony-stimulating factor primes NADPH oxidase in neutrophils throught translocation of cytochrome b558 by gelatinasegranule release / P.J. Mansfield, V. Hinkovska-Galeheva, J.A. Shayman, L.A. Boxer //J Lab. Clin.Med.-2002.-V.140.-P.9-16.
123.Grigoriu, M. Periampullar diverticulum-related to bilio-pancreatic disorders/ M. Grigoriu, R. Palade, C. Lutic // Chirurgia (Bucur) -2010.-V.105.-№1.-P.37-43.
124.Hajime, N. Priming effect of Pseudomonas aeruginosa leukocidin on chemilumenescense response of zymosan or PMA-stimulated rabbit PNL / N.
143
Hajime, K. Otohico, N. Masatoshi //Jap J Med Science and Biology.-1991.-V.44.-
№5-P.252.
125.Inflammatory cytokines, C-reactive protein, and procalcitonin as early predictors of necrosis infection in acute pancreatitis/ F.C. Riche, B.P. Cholley, M.J. Laisne, et al. //Surgery.-2003.-V.133.-№3.-P.257-262.
126.Inflammatory mediators in acute pancreatitis / M. Bhatia, M. Brady, S. Shokuhi, et al.// J. Pathology.- 2000.- V.190.- P. 117–125.
127.Interdigestive small bowel motility and duodenal bacterial overgrowth in experimental acute pancreatitis / I.D. Van Felius, L.M. Akkermans, K. Bosscha, et al. // Neurogastroenterol Motil.- 2003-.V.15.-№3.-P.267–276.
128.Intracapillary leukocyte accumulation as a novel antihaemorrhagic mechanism in acute pancreatitis in mice/ E. Ryschich, V. Kerkadze, O. Deduchovas, et al. // Gut.-2009.-V.58.-№11.- P.1508-1516.
129.Iwata, T. Chemiluminescent detection of induced reactive oxygen metabolite production of human polymorphonuclear leucocytes by anthophyllite asbestos / T. Iwata, N. Kohyama, E. Yano //Environmental research.-2002.-V.-88.-№1.- P.36-40.
130.Lunel, F. Activation oxidant metabolism in phagocytes opsonizated by Plasmodium falciparum/ F. Lunel, Descamps-Latscha., P. Druilhe // Acta trop.-1990.- V.47.-№2.- P.61-68.
131.Marsha, A. Protein A activates membrane bound multicomponents enzyme complex NADPH-oxidase in human neutrophils/ A. Marsha // Immunopharm. and Immunotox. -1999. -V.21. -№4.- P.683–694.
132.McPhail, L. Role NADPH - oxidase of human polymorphonuclear leukocytes/ L. McPhail, C.C. Clayton // J. Biol. Chem. – 1984.-V. 72. - № 1. – P.192 -197.
133.Morel, J Doussierre. The superoxide-generating oxidase in phagocytic cells. Physiologic, molecular and pathological aspects/ J. Doussierre Morel, P.V. Vignais // Eur. J. Biochem. – 1991. – V.202. - №3. -P. 523-546.
144
134.Neutrophils exposed to bacterial lipopolysacharide upregulation NADPH oxidase assembly/ F.R. Deleo, J. Rence, S. McCormick, et al. //J Clin Ivest.-1998.-V.101- P.455-463.
135.On the absorption of bacterial endotoxin from the gastro-intestinal tract of the normal and shocked animal/ H.A. Ravin, D. Rowley, C. Jenkins, J. Fine // J. Exp. Med.-1960.-V.112.-P.783–792.
136.Pancreatic sepsis: prevention and therapy / B. Gloor, A.B. Schmidtmann, M. Worni et al. //Best Pract &Res.Clin.Gastroenterol.-2002.-V.16.-№3. -P. 379-390.
137.Potential role of reactive oxygen species in pancreatitis-associated multiple organ dysfunction / C. Shi, R. Andersson, X. Zhao, X.Wang //Pancreatology.- 2005.- V.5.-№4.- P.492-500.
138.Rinderknecht, H. Fatal pancreatitis, a consequence of excessive leukocyte stimulation?/ H. Rinderknecht //Int. J.Pancreatol. -1988.-V.3.-P.105-112.
139.Role of procalcitonin and granulocyte colony stimulating factor in the early prediction of infected necrosis in severe acute pancreatitis/ C. Muller, W. Uhl, G. Printzen, et al. // Gut. -2000.-V.46.- P.233-238.
140.Role of neutrophils in ceruleininduced pancreatitis in rats: possible involment of apoptosis / K. Fujimoto, R. Hosotani, R. Doi, M. Wada, et al. //Pancreatology.- 1997.- №58. – P.421-430.
141.Role of reactive oxygen species in the pathogenesis of caerulein-induced acute pancreatitis/ A. Dabrowski, P.C. Konturek, S.J. Konturek, A. Gabryelewicz // Acute Pancreatitis. Novel Concepts in Biology and Therapy. Berlin. Blackwell. - 1999. - P. 77–87.
142.Sakorafas, G.H. Etiology and pathogenesis of acute pancreatitis: current concepts/ G.H. Sakorafas, A.G. Tsiotou //J.Clin.Gastroenterology - 2000.- V.30. –P.343– 356.
143.Schoenberg, M.H. Oxygen radicals in experimental acute pancreatitis / M.H. Schoenberg, M. Büchler, H.G. Beger //Hepatogastroenterology. - 1994. – V.41. –
Р.313–319.
145
144.Schoenberg, M.H. The role oxygen radicals in experimental acute pancreatitis/ Schoenberg, M. Büchler, H.G. Beger //Free Radic. Biolog. Med.-1992.-V.12.-
№6.-P.515-522.
145.Severe acute pancreatitis: the life after/ R. Gurta, J.D. Wig, D.K. Bhasin, et al. //J Gastrointest Surg.-2009.-V.13. - №7.- P.1328-1336.
146.Sochor, M. Inhibition of matrix metalloproteinase-9 with doxycycline reduces pancreatitis-associated lung injury/ M. Sochor, S. Richter, A. Schmidt // Diges- tion.-2009.- V. 80.-№2.- P.65-73.
147.Targeted disruption of the beta-chemokine receptor CCR1 protects against pan- creatitis-associated lung injury / C. Gerard, J.L. Frossard, M. Bhatia, et al. // J. Clin. Invest.- 1997.-V.100. –P. 2022–2027.
148.The dynamic of the oxidant-antioxidant balance in the early phase of human acute biliary pancreatitis / A. Dziurkowska-Marek, T.A. Marek, A. Nowak, et al. //Pancreatology.- 2004.-V.4.-№4.- P. 215-222.
149.The fist histological demonstration of pancreatic oxidative stress in human acute pancreatitis / K. Telek, J RegolyMerei, G.C. Kovacs, et al.// Hepatogastroenterology.-2001.-V.48.-P.1252-1258.
150.The pancreas misled: signal to pancreatitis / D.N. Criddle, E. McLayhlin, J.A. Murphy, et al. //Pancreatology. - 2007.-V.7.-P.436-446.
151.The potencial role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis/ B.M. Rau, G. Steinbach, F. Gansauge, et al. //Gut.- 1997.-V.41.-№6.-P.832-840.
152.The response of tuberculosis patient neutrophils to the bacilli Calmette-Guerin stimulation / K. Zabuska, A. Ponahajba, et al. // Int.J.Tuberc.and Lung diasease.- 1999.-V.3.-№3.-P.183.
153.The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury / J-L. Frossard, A. Saluja, L. Bhagat, et al. //Gastroenterology. -1999.-V.116.-P.694-701.
146
154.The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis / D. Sandoval, A. Gukovskaya, P. Reavey, et al. //Gastroenterology. - 1996.- V.111 - Р.1081–1091.
155.The role of polymorphonuclear leukocytes and oxygen-derived free radicals in experimental acute pancreatitis: mediators of local destruction and activators of inflammation/ B. Poch, F. Gansauge, B. M. Rau, et al. //FEBS Letters. – 1999. – V.461. –P.268-272.
156.Treatment with Met-RANTES reduces lung injury in caerulein induced pancreatitis in mice / M. Bhatia, A.E. Proudfoot, T.N.C.Wells, et al. // Brit. J. Surg.- 2003.- V. 90.- P. 698–704.
157.Upregulation of costimulatory molecules induced by lipopolysaccharide and dou- ble-stranded RNA occurs by Trif-dependent and Trif-independent pathways/ K. Hoebe, E. Janssen, S.O. Kim, et al. //Nature Immunology. - 2003.- V.4.- №12.- P.1223-1229.
158.Wilson, P.G. Acute pancreatitis as a model of sepsis. / P.G. Wilson, M. Manji, J.P. Neoptolemos //J Antimicrob Chemother.- 1998.-V.41(SupplA). - P.51–63.
ПРИЛОЖЕНИЕ. Таблица 1.
Сравнение индексов соотношения площадей Л-ХЛ ПМЛ крови больных с асептическим и инфицированным течением ОДП при воздействии комплексного АГ Escherichia coli. (M ± m).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Сроки наблюдения (сутки стационарного лечения) |
|
|
|
|
|
|
|||||||
САГ, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
микр.кл/мл, |
|
Доноры |
|
|
1 сутки |
|
|
|
7 сутки |
|
|
|
14 сутки |
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
×104 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 группа |
|
P< |
2 группа |
1 группа |
P< |
|
2 группа |
1 группа |
|
P< |
|
2 группа |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
147 |
|
|
|
|
|
2,45 ± 0,07# |
|
|
|
|
2,40 ± 0,07# |
|
|
|
|
|
|
|
|
|
||
5 |
|
1,85 ± 0,11 |
|
|
0,001 |
1,10 ± 0,06# |
|
0,001 |
|
1,69 ± 0,08 |
|
2,15 ± 0,008* |
|
0,001 |
|
1,60 ± 0,01* |
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50 |
|
1,69 ± 0,12 |
|
2,08 ± 0,07* |
|
0,001 |
1,45 ± 0,06 |
|
2,30 ± 0,06# |
0,001 |
|
1,82 ± 0,05 |
|
1,91 ± 0,03# |
|
0,001 |
|
1,58 ± 0,02* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
250 |
|
|
1,83 ± 0,14* |
|
|
0,88 ± 0,08# |
|
2,23 ± 0,16# |
|
|
1,57 ± 0,09* |
|
1,71 ± 0,03# |
|
|
|
1,48 ± 0,03 |
|
|
|
|
1,39 ± 0,07 |
|
|
0,001 |
|
0,001 |
|
|
|
0,001 |
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
|
0,89 ± 0,05 |
|
2,13 ± 0,04# |
|
0,001 |
0,68 ± 0,04# |
|
2,96 ± 0,06# |
0,001 |
|
0,83 ± 0,04* |
|
1,53 ± 0,008# |
|
0,001 |
|
0,84 ± 0,03* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Примечание: * - р<0,05; # - p<0,001 по сравнению с группой доноров.
ПРИЛОЖЕНИЕ. Таблица 2.
Сравнение индексов соотношения площадей Л-ХЛ ПМЛ крови больных с асептическим и инфицированным течением
ОДП при воздействии комплексного АГ Staphylococcus aureus. (M ± m).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Сроки наблюдения (сутки стационарного лечения) |
|
|
|
|
|
|
|
|
|||||||||
САГ, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
микр.кл/мл, |
Доноры |
|
|
1 сутки |
|
|
|
7 сутки |
|
|
|
|
14 сутки |
|
|
||||||||||
×104 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 группа |
|
Р< |
|
|
2 группа |
|
1 группа |
|
|
Р< |
|
2 группа |
|
1 группа |
|
|
Р< |
|
|
2 группа |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 |
2,13 ± 0,27 |
1,43 ± 0,11* |
|
0,05 |
|
|
1,24 ± 0,02* |
1,35 ± 0,11* |
|
|
0,001 |
|
2,33 ± 0,04 |
2,15 |
± 0,04 |
|
|
0,001 |
|
|
0,94 ± 0,04# |
148 |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
50 |
1,21 ± 0,09 |
1,35 ± 0,07* |
|
0,05 |
|
|
0,92 ± 0,07* |
1,69 ± 0,19* |
|
|
0,05 |
|
1,22 ± 0,05 |
1,22 |
± 0,04 |
|
|
0,001 |
|
|
0,71 ± 0,04# |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
250 |
0,73 ± 0,05 |
1,25 ± 0,16* |
|
0,001 |
|
|
0,44 ± 0,04# |
1,48 ± 0,06# |
|
|
0,001 |
|
0,87 ± 0,03* |
0,82 ± 0,01* |
|
|
0,001 |
|
|
0,60 ± 0,03* |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
1000 |
0,31 ± 0,04 |
1,09 ± 0,05# |
|
0,001 |
|
|
0,10 ± 0,002# |
1,82 ± 0,01# |
|
|
0,001 |
|
0,22 ± 0,005* |
0,41 ± 0,03* |
|
|
0,001 |
|
|
0,22 ± 0,01* |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Примечание: * -р<0,05; # -p<0,001 по сравнению с группой доноров.
ПРИЛОЖЕНИЕ. Таблица 3.
Сравнение индексов соотношения площадей Л-ХЛ ПМЛ крови больных с асептическим и инфицированным ОДП при
воздействии комплексного АГ Klebsiella pneumoniae. (M ± m).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Сроки наблюдения (сутки стационарного лечения) |
|
|
|
|
|
|
|
|
||||||||
САГ, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
микр.кл/мл, |
|
Доноры |
|
|
|
1 сутки |
|
|
|
7 сутки |
|
|
|
14 сутки |
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
×104 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 группа |
|
Р< |
|
2 группа |
1 группа |
|
P< |
|
2 группа |
1 группа |
|
|
P< |
|
|
2 группа |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 |
|
2,80 ± 0,21 |
|
2,26 ± 0,10* |
|
0,1 |
|
2,11 ± 0,02* |
|
2,38 ± 0,05* |
|
0,05 |
|
2,19 ± 0,05* |
|
2,86 ± 0,04 |
|
|
0,05 |
|
|
1,99 ± 0,23* |
|
149 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
50 |
|
|
2,26 ± 0,34* |
|
|
1,97 ± 0,16* |
|
1,54 ± 0,07* |
|
|
2,21 ± 0,05* |
|
2,95 ± 0,04 |
|
|
|
|
1,77 ± 0,05# |
|
|
||||
|
3,04 ± 0,30 |
|
|
0,1 |
|
|
|
0,001 |
|
|
|
|
0,001 |
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
250 |
|
2,11 ± 0,26 |
|
1,53 ± 0,15* |
|
0,05 |
|
1,19 ± 0,07* |
|
1,39 ± 0,10# |
|
0,05 |
|
0,96 ± 0,02# |
|
2,28 ± 0,07 |
|
|
0,001 |
|
|
1,03 ± 0,12# |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
1000 |
|
1,02 ± 0,18 |
|
1,83 ± 0,17# |
|
0,001 |
|
0,58 ± 0,02* |
|
1,57 ± 0,10* |
|
0,001 |
|
0,73 ± 0,09* |
|
1,23 ± 0,05 |
|
|
0,001 |
|
|
0,63 ± 0,05* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Примечание: *-р<0,05; #-p<0,001 по сравнению с группой доноров.
ПРИЛОЖЕНИЕ. Таблица 4.
Сравнение индексов соотношения площадей Л-ХЛ ПМЛ крови больных с асептическим и инфицированным ОДП при воздействии комплексного АГ Pseudomonas aeruginosa. (M ± m).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Сроки наблюдения (сутки стационарного лечения) |
|
|
|
|
|
|||||||
САГ, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
микр.кл/ |
|
Доноры |
|
|
1 сутки |
|
|
|
|
7 сутки |
|
|
|
14 сутки |
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
мл, ×104 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 группа |
P< |
|
2 группа |
1 группа |
|
P< |
2 группа |
1 группа |
P< |
|
2 группа |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150 |
5 |
|
1,51 ± 0,05 |
|
1,11 ± 0,12# |
0,01 |
|
0,67 ± 0,05# |
|
1,24 ± 0,09# |
|
0,001 |
0,61 ± 0,02# |
|
1,21 ± 0,08# |
0,05 |
|
0,97 ±0,10* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
50 |
|
1,16 ± 0,10 |
|
1,29 ± 0,12 |
0,05 |
|
0,92 ± 0,08* |
|
1,25 ± 0,09 |
|
>0,05 |
1,12 ± 0,06 |
|
1,32 ± 0,02# |
0,001 |
|
1,02 ± 0,01* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
250 |
|
|
|
1,57 ± 0,12# |
|
|
0,70 ± 0,02 |
|
1,83 ± 0,05# |
|
|
0,79 ± 0,03 |
|
1,51 ± 0,04# |
|
|
1,01 ± 0,04* |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
0,82 ± 0,08 |
|
0,001 |
|
|
|
0,001 |
|
0,001 |
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
1000 |
|
0,40 ± 0,05 |
|
1,87 ± 0,17# |
0,001 |
|
0,47 ± 0,008* |
|
2,31 ± 0,17# |
|
0,0001 |
0,61± 0,008# |
|
1,87 ± 0,04# |
0,001 |
|
0,86 ± 0,04# |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Примечание: *-р<0,05; #-p<0,001 по сравнению с группой доноров.